Drug-maker Orchid Chemicals and Pharmaceuticals Ltd is set to redefine its growth path, after the sale of its injectibles business to Hospira last year. Now Orchid has acquired the USbased generics marketing company, Karalex Pharma, for an undisclosed sum.
The acquisition will give Orchid a front-end in the
Orchid will launch two products (oral cephalosporins and non-antibiotics) this year, through this company, and expects to add $20 million to its revenues this year and about $100 million in the next three years.
The products Orchid looks to sell are in therapeutic areas such as the central nervous system, cardio-vascular system, anti-diabetic and antiinflammatory sectors. Karalex had clocked revenues of $10 million up to December 2009, said a company official.
Orchid recently completed its $400-million transaction with Hospira, where it had sold its injectibles business worth $90 million to the company. Orchid is left with business worth $300 million, he said, about 80 per cent of its business.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: